• Nautilus Biotechnology posted a net loss of USD 14.47 million for Q2 2026, narrowing 4% year over year, while revenue turned positive at USD 190,000.
• Operating expenses fell 7% to USD 15.94 million, led by an 8% drop in research and development to USD 9.61 million.
• Selling, general and administrative costs declined 6% to USD 6.33 million, while interest income slid 37% to USD 1.31 million.
• It launched an Iterative Mapping Early Access Program with Tau service offerings, adding initial sales hires and targeting pre-orders in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001808805-26-000034), on July 28, 2026, and is solely responsible for the information contained therein.